Views & Analysis | Perspectives on pharma industry issues

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

R&D

GLP-1 RAs in CKM management: A Q&A with CORXEL

GLP-1 RA medicine has transformed treatment of metabolic diseases such as obesity and diabetes. We spoke with China's CORXEL about theirs.

Patients

Longevity as the new health paradigm: The control system

Nutrition shapes the biology of ageing; lifestyle determines how that biology is expressed

Digital

Nurse affixes a smart device to an elderly patient's wrist

Smaller, smarter devices for global trial diversity

Consumer device giants are surging into the healthcare arena to make devices cheaper, more compact, and easier for patients to use.

Digital

Built around the NHS ward: 5 Norwegian healthtech innovators

Norwegian healthtech companies are operating inside NHS trusts – tackling everyday problems that shape care.

R&D

JPM: The calm before the storm for radiotherapeutics

Radiotherapeutics have tremendous potential, but only a few therapies in market. But the technology is getting closer to its breakthrough moment.

R&D

Magnifying glass over years including 2026

Looking ahead to 2026 in biopharma

A look forward to trends to come in 2026, including AI-driven drug development, advanced modalities, and cardiometabolic disease therapies.

R&D

Is this the year for precision psychology? With Amit Etkin

At the Sachs Neuroscience Forum just before the start of JPM 2026 in San Francisco, pharmaphorum spoke with Amit Etkin, CEO of Alto Neuroscience.

Sales & Marketing

M&A trends in diagnostics and life sciences tools

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

Sales & Marketing

What does FDA's proposed DTC advertising rule mean for pharm...

Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.

Digital

Australia, AI, and Autolomous

pharmaphorum spoke with Alexander Seyf, CEO of Autolomous, about the future of AI in Australian biotech.

Digital

Smaller, smarter devices for global trial diversity

Consumer device giants are surging into the healthcare arena to make devices cheaper, more compact, and easier for patients to use.

Market Access

Europe’s new HTA reality: The JCA, one year on

Here, we examine the early realities of JCA implementation, exploring whether the system is delivering greater alignment across European markets.

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs

Oncology

Key lessons from EHA 2026: Translating evidence into impact

Across four days in Sweden, EHA 2026 offered a clear view of the future of blood cancer care.

Oncology

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

radiotherapy session for young man with cancer

Early diagnosis means little without timely treatment

Early diagnosis only changes outcomes if it is followed by timely treatment.

Patients

Longevity as the new health paradigm: The control system

Nutrition shapes the biology of ageing; lifestyle determines how that biology is expressed

Patients

12 Questions with Kim Innes

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

Patients

Why Britain's blood tests are only as reliable as the journe...

What happens in phlebotomy has a huge impact in pathology, and the different funding streams and management means that interests are no longer aligned

Australia, AI, and Autolomous

GLP-1 RAs in CKM management: A Q&A with CORXEL

Longevity as the new health paradigm: The control system

Smaller, smarter devices for global trial diversity

Built around the NHS ward: 5 Norwegian healthtech innovators

JPM: The calm before the storm for radiotherapeutics

Looking ahead to 2026 in biopharma

Is this the year for precision psychology? With Amit Etkin

M&A trends in diagnostics and life sciences tools

What does FDA's proposed DTC advertising rule mean for pharm...

Australia, AI, and Autolomous

Smaller, smarter devices for global trial diversity

Europe’s new HTA reality: The JCA, one year on

Why global pharmaceutical reforms are quietly redirecting ra...

Key lessons from EHA 2026: Translating evidence into impact

Establishing ctDNA as a validated primary surrogate endpoint

Early diagnosis means little without timely treatment

Longevity as the new health paradigm: The control system

12 Questions with Kim Innes

Why Britain's blood tests are only as reliable as the journe...

GLP-1 RAs in CKM management: A Q&A with CORXEL

Clinical Trials Round-Up: May and June 2026

Integrate or isolate: Incorporating traditional safety-relat...

Insmed partners patient group on bronchiectasis study

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks